Kexing Biopharm Co., Ltd.
Clinical trials sponsored by Kexing Biopharm Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company developing vaccines and biological products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Inhaled interferon could be new weapon against severe RSV in young children Results expected Jun 2027 (estimated) 🚀 Make-or-break
-
Inhaled interferon could be new weapon against severe RSV in young children
Disease control Recruiting nowThis phase 3 trial tests whether an inhaled solution of human interferon α1b can safely help children under 2 years old recover from respiratory syncytial virus (RSV) lower respiratory tract infections. The study compares the interferon treatment to a placebo, measuring improveme…
Phase 3 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New growth hormone treatment for short children enters final testing phase
Disease control Recruiting nowThis study tests a new growth hormone injection (GB06) in 192 children aged 3 to 11 with growth hormone deficiency, a condition that causes slow growth. The treatment is given daily for 52 weeks to see if it helps children grow taller at a similar rate to an existing approved hor…
Phase 3 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New shot aims to reverse cancer wasting
Symptom relief Recruiting nowThis early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…
Phase 1 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC